Although preclinical studies revealed that molecules acting through epigenetic mechanisms, i.e., DNA methyltransferases or HDAC inhibitors, might have therapeutic potential, they are not used in schizophrenia therapy (DNA methyltransferase) or they are subject to clinical trials (HDAC inhibitors). This evidence concerns the gene HDAC9 and schizophrenia.